

Obesity Portfolio Gaps in Big Pharma

 Portfolio gap

Top 10 Pharma	Commercial	Late-Stage Dev (Ph2+)	Early-Stage Dev
	Tirzepatide (GLP-1R / GIPR); Mazdutide (GLP-1R / GCCR / OXM)	Orforglipron (GLP-1R oral); Retatrutide (GLP-1R / GIPR / GCCR); Eloralintide (AMYR); LY307161 (GLP-1 / GLP-1R); LY3549492 (GLP-1R); Bimagrumb (activin type II)	Nisotirostide (PYY); Macupatide (GIPR); LY3537031 (GLP-1R / GIPR); LY4086940 (N/A); Patent-mined (UCN2); HAYA Tx Program (N/A); Fauna Bio Program (N/A)
			
			GUB014295 (Amylin)
		Petrelintide (Amylin); CT-868 (GLP-1R / GIPR); CT-388 (GLP-1R / GIPR); CT-996 (GLP-1R)	CT-859 (GLP-1R / GIPR); Patent Mined (NPY2R)
		AZD5004 (GLP-1R); AZD6234 (Amylin); AZD9550 (GLP-1R / GCGR)	AZD4144 (NLRP3); AZ12861903 (GHSR); AZ13483342 (MCHR1); AZD3857 (MCHR1 / AChE); Patent Mined (GPR75)
			Patent Mined (GLP-1R)
	Semaglutide (GLP-1R); Liraglutide (GLP-1R)	Cagrisema (Amylin / GLP-1R); Semaglutide (GLP-1R Oral); Cagrilintide (Amylin); Amycretin (GLP-1R / AMYR); NN0519-0130 (GLP-1R / GIPR); UBT251 (GLP-1R / GIPR / GCGR); Monlunabant (CB1)	NNC0662-0419 (GLP-1 / GIP / glucagon); NNC0638-0355 (N/A); NNC0174-1213A (AMYR); Amylin 355 (Amylin); GLP1R-LEPR; LX9851 (ACSL5); SP-2297 (GLP-1R / GCGR / GIPR); Patent Mined (UCN2 / CRHR2); Deep Apple Program (N/A); INV-347 (CB1)
			Efinopegdutide (GLP-1R / GCGR / OXM), MK-4082 (GLP-1R); MK-1462 (GLP-1R / GCGR)
		MariTide (GLP-1R / GIPR)	AMG-786 (N/A); AMG-513 (N/A); Patent Mined (CB1); Patent Mined (FAM13A)
		PF-07976016 (GIPR)	Patent Mined (GIPR); Patent Mined (GLP-1R / GIPR)

Sleuth

<https://sleuthinsights.com/>

Note: Stage of development reflects highest globally, IST studies only